USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma

Abstract

BackgroundUbiquitination is a reversible process of posttranslational protein modification through the action of the family of deubiquitylating enzymes which contain ubiquitin-specific protease 9x (USP9X). Recent evidence indicates that USP9X is involved in the progression of various human cancers. The aim was to detect the expression of USP9X in the progression from normal epithelium to invasive esophageal squamous cell cancer (ESCC) and evaluate the relevance of USP9X expression to the tumor progression and prognosis.MethodsIn this study, USP9X immunohistochemical analysis was performed on tissues constructed from ESCC combined with either normal epithelium or adjacent precursor tissues of 102 patients. All analyses were performed by SPSS 13.0 software.ResultsWe observed that the level of high USP9X expression increased gradually in the transformation from normal epithelium (4.0%), to low grade intraepithelial neoplasia (10.5%), then to high grade intraepithelial neoplasia (28.6%), and finally to invasive ESCC (40.2%). The expression of USP9X was found to be significantly different between the normal mucosa and ESCC (P < 0.001), and between low grade intraepithelial neoplasia and high grade intraepithelial neoplasia (p = 0.012). However, no difference was observed between the high expression of USP9X in normal mucosa and low grade intraepithelial neoplasia (P = 0.369), nor between high grade intraepithelial neoplasia and ESCC (p = 0.115). Interestingly, the most intensive staining for USP9X was usually observed in the basal and lower spinous layers of the esophageal epithelium with precursor lesions which often resulted in the earliest malignant lesion. USP9X expression status was positively associated with both depth of invasion (p = 0.046) and lymph node metastasis (p = 0.032). Increased USP9X expression was significantly correlated to poorer survival rate in ESCC patients (p = 0.001). When adjusted by multivariate analysis, USP9X expression (HR 2.066, P = 0.005), together with TNM stage (HR 1.702, P = 0.042) was an independent predictor for overall survival.ConclusionsUp-regulation of USP9X plays an important role in formation and progression of precancerous lesions in ESCC and USP9X expression levels were significantly correlated with the survival of ESCC patients. Thus, USP9X could be considered as a potential biomarker and prognostic predictor for ESCC.Virtual slidesThe virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1945302932102737

Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma

“…Mounting evidence suggests that USP9X behaves principally as an oncogene in the context of many neoplasms. Studies have demonstrated that USP9X levels correlate with tumor cell growth and staging in a number of cancers including lung, 26 breast, 27 cervical, 22 chronic myelogenous leukemia, 24 colon, 28 esophageal carcinoma, 29 brain, 5 and to a limited extent, PDAC. 1 The data presented in this report supports the role of USP9X as a growth promoter in the context of PDAC.…”

Naturally Occurring Isothiocyanates Exert Anticancer Effects by Inhibiting Deubiquitinating Enzymes

“…Both USP9x and UCH37 are over-expressed in many cancers(30–33), so inhibition of these DUBs provides an attractive mechanism for the anticancer effects of ITCs (30,31,33). USP9x is known to protect the antiapoptotic protein Mcl-1 from ubiquitination and degradation(33).…”

Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome

“…Nevertheless, Xlinked deubiquitinase USP9X, the allele of USP9Y, has been reported to serve as a tumor suppressor gene in pancreatic ductal adenocarcinoma [34]. Moreover, recent studies have demonstrated a correlation between US9X expression and the formation, progression, and poor prognosis of ESCC (esophageal squamous cell carcinoma) [35]. In prostate cancer, it could stabilize ERG, which is a major driver of prostate cancer [36].…”